Logo image of INVA

INNOVIVA INC (INVA) Stock Fundamental Analysis

NASDAQ:INVA - Nasdaq - US45781M1018 - Common Stock - Currency: USD

19.94  +0.36 (+1.84%)

Fundamental Rating

6

Overall INVA gets a fundamental rating of 6 out of 10. We evaluated INVA against 193 industry peers in the Pharmaceuticals industry. INVA has an excellent financial health rating, but there are some minor concerns on its profitability. INVA may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make INVA suitable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

INVA had negative earnings in the past year.
In the past year INVA had a positive cash flow from operations.
In the past 5 years INVA has always been profitable.
Each year in the past 5 years INVA had a positive operating cash flow.
INVA Yearly Net Income VS EBIT VS OCF VS FCFINVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

1.2 Ratios

INVA has a Return On Assets of -4.76%. This is in the better half of the industry: INVA outperforms 75.13% of its industry peers.
INVA has a better Return On Equity (-9.23%) than 77.72% of its industry peers.
INVA's Return On Invested Capital of 13.88% is amongst the best of the industry. INVA outperforms 91.71% of its industry peers.
INVA had an Average Return On Invested Capital over the past 3 years of 11.38%. This is below the industry average of 14.87%.
The last Return On Invested Capital (13.88%) for INVA is above the 3 year average (11.38%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -4.76%
ROE -9.23%
ROIC 13.88%
ROA(3y)11.21%
ROA(5y)16.95%
ROE(3y)22.61%
ROE(5y)34.7%
ROIC(3y)11.38%
ROIC(5y)18.16%
INVA Yearly ROA, ROE, ROICINVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200

1.3 Margins

In the last couple of years the Profit Margin of INVA has declined.
Looking at the Operating Margin, with a value of 49.34%, INVA belongs to the top of the industry, outperforming 98.96% of the companies in the same industry.
INVA's Operating Margin has declined in the last couple of years.
INVA's Gross Margin of 90.68% is amongst the best of the industry. INVA outperforms 94.82% of its industry peers.
Industry RankSector Rank
OM 49.34%
PM (TTM) N/A
GM 90.68%
OM growth 3Y-21.38%
OM growth 5Y-13.2%
PM growth 3Y-54.19%
PM growth 5Y-35.9%
GM growth 3YN/A
GM growth 5YN/A
INVA Yearly Profit, Operating, Gross MarginsINVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), INVA is creating some value.
The number of shares outstanding for INVA has been reduced compared to 1 year ago.
Compared to 5 years ago, INVA has less shares outstanding
INVA has a better debt/assets ratio than last year.
INVA Yearly Shares OutstandingINVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
INVA Yearly Total Debt VS Total AssetsINVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

INVA has an Altman-Z score of 2.27. This is not the best score and indicates that INVA is in the grey zone with still only limited risk for bankruptcy at the moment.
INVA's Altman-Z score of 2.27 is fine compared to the rest of the industry. INVA outperforms 67.36% of its industry peers.
The Debt to FCF ratio of INVA is 2.29, which is a good value as it means it would take INVA, 2.29 years of fcf income to pay off all of its debts.
INVA has a Debt to FCF ratio of 2.29. This is amongst the best in the industry. INVA outperforms 93.26% of its industry peers.
INVA has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.40, INVA perfoms like the industry average, outperforming 40.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF 2.29
Altman-Z 2.27
ROIC/WACC1.57
WACC8.87%
INVA Yearly LT Debt VS Equity VS FCFINVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

INVA has a Current Ratio of 2.48. This indicates that INVA is financially healthy and has no problem in meeting its short term obligations.
INVA has a Current ratio of 2.48. This is comparable to the rest of the industry: INVA outperforms 43.52% of its industry peers.
A Quick Ratio of 2.30 indicates that INVA has no problem at all paying its short term obligations.
INVA's Quick ratio of 2.30 is in line compared to the rest of the industry. INVA outperforms 47.15% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.3
INVA Yearly Current Assets VS Current LiabilitesINVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for INVA have decreased strongly by -145.50% in the last year.
Measured over the past years, INVA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -33.21% on average per year.
Looking at the last year, INVA shows a quite strong growth in Revenue. The Revenue has grown by 18.68% in the last year.
Measured over the past years, INVA shows a small growth in Revenue. The Revenue has been growing by 6.57% on average per year.
EPS 1Y (TTM)-145.5%
EPS 3Y-52.04%
EPS 5Y-33.21%
EPS Q2Q%-260.87%
Revenue 1Y (TTM)18.68%
Revenue growth 3Y-2.91%
Revenue growth 5Y6.57%
Sales Q2Q%14.37%

3.2 Future

The Earnings Per Share is expected to grow by 99.32% on average over the next years. This is a very strong growth
INVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.46% yearly.
EPS Next Y259.68%
EPS Next 2Y279.31%
EPS Next 3Y166.36%
EPS Next 5Y99.32%
Revenue Next Year3.16%
Revenue Next 2Y7.79%
Revenue Next 3Y10.57%
Revenue Next 5Y14.46%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INVA Yearly Revenue VS EstimatesINVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
INVA Yearly EPS VS EstimatesINVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

INVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 7.29, the valuation of INVA can be described as very cheap.
Based on the Price/Forward Earnings ratio, INVA is valued cheaply inside the industry as 90.16% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 35.58. INVA is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 7.29
INVA Price Earnings VS Forward Price EarningsINVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, INVA is valued cheaply inside the industry as 97.93% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of INVA indicates a rather cheap valuation: INVA is cheaper than 95.85% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.39
EV/EBITDA 4.96
INVA Per share dataINVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of INVA may justify a higher PE ratio.
A more expensive valuation may be justified as INVA's earnings are expected to grow with 166.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y279.31%
EPS Next 3Y166.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNOVIVA INC

NASDAQ:INVA (7/15/2025, 10:54:07 AM)

19.94

+0.36 (+1.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-30 2025-07-30
Inst Owners109.95%
Inst Owner Change0%
Ins Owners1.06%
Ins Owner Change1.18%
Market Cap1.25B
Analysts82.86
Price Target56.1 (181.34%)
Short Float %16.47%
Short Ratio11.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-190.64%
Min EPS beat(2)-350.17%
Max EPS beat(2)-31.11%
EPS beat(4)0
Avg EPS beat(4)-200.83%
Min EPS beat(4)-350.17%
Max EPS beat(4)-31.11%
EPS beat(8)3
Avg EPS beat(8)-31.34%
EPS beat(12)5
Avg EPS beat(12)-64.48%
EPS beat(16)7
Avg EPS beat(16)-34.55%
Revenue beat(2)2
Avg Revenue beat(2)4.4%
Min Revenue beat(2)3.7%
Max Revenue beat(2)5.11%
Revenue beat(4)4
Avg Revenue beat(4)13.51%
Min Revenue beat(4)3.7%
Max Revenue beat(4)31.13%
Revenue beat(8)7
Avg Revenue beat(8)10.16%
Revenue beat(12)9
Avg Revenue beat(12)-0.41%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)48.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)30.3%
EPS NY rev (1m)0%
EPS NY rev (3m)-58.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.29
P/S 3.38
P/FCF 6.39
P/OCF 6.25
P/B 1.94
P/tB 3.47
EV/EBITDA 4.96
EPS(TTM)-1.01
EYN/A
EPS(NY)2.73
Fwd EY13.71%
FCF(TTM)3.12
FCFY15.66%
OCF(TTM)3.19
OCFY16%
SpS5.89
BVpS10.3
TBVpS5.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.76%
ROE -9.23%
ROCE 17.9%
ROIC 13.88%
ROICexc 24.72%
ROICexgc 49.43%
OM 49.34%
PM (TTM) N/A
GM 90.68%
FCFM 52.99%
ROA(3y)11.21%
ROA(5y)16.95%
ROE(3y)22.61%
ROE(5y)34.7%
ROIC(3y)11.38%
ROIC(5y)18.16%
ROICexc(3y)16.17%
ROICexc(5y)24.46%
ROICexgc(3y)28.95%
ROICexgc(5y)34.96%
ROCE(3y)14.67%
ROCE(5y)23.41%
ROICexcg growth 3Y-8.78%
ROICexcg growth 5Y-15.28%
ROICexc growth 3Y-21.15%
ROICexc growth 5Y-17.48%
OM growth 3Y-21.38%
OM growth 5Y-13.2%
PM growth 3Y-54.19%
PM growth 5Y-35.9%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF 2.29
Debt/EBITDA 1.15
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 17.62
Cash Conversion 90.06%
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.3
Altman-Z 2.27
F-Score6
WACC8.87%
ROIC/WACC1.57
Cap/Depr(3y)4.13%
Cap/Depr(5y)2.48%
Cap/Sales(3y)0.45%
Cap/Sales(5y)0.27%
Profit Quality(3y)320.3%
Profit Quality(5y)247.45%
High Growth Momentum
Growth
EPS 1Y (TTM)-145.5%
EPS 3Y-52.04%
EPS 5Y-33.21%
EPS Q2Q%-260.87%
EPS Next Y259.68%
EPS Next 2Y279.31%
EPS Next 3Y166.36%
EPS Next 5Y99.32%
Revenue 1Y (TTM)18.68%
Revenue growth 3Y-2.91%
Revenue growth 5Y6.57%
Sales Q2Q%14.37%
Revenue Next Year3.16%
Revenue Next 2Y7.79%
Revenue Next 3Y10.57%
Revenue Next 5Y14.46%
EBIT growth 1Y66.31%
EBIT growth 3Y-23.66%
EBIT growth 5Y-7.5%
EBIT Next Year-6.31%
EBIT Next 3Y-8.15%
EBIT Next 5YN/A
FCF growth 1Y51.7%
FCF growth 3Y-20.27%
FCF growth 5Y-6.46%
OCF growth 1Y54.88%
OCF growth 3Y-19.65%
OCF growth 5Y-6.03%